MBX Biosciences Inc(MBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:17 PM ET (Korea 10/28 05:17)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.41 | Insider Own | 36.67% | Shs Outstand | 48.0M | Perf Week | -0.99% |
| Market Cap | 2.55B | Forward P/E | - | EPS next Y | -29.74% | Insider Trans | -0.4% | Shs Float | 30.5M | Perf Month | -7.94% |
| Enterprise Value | 2.14B | PEG | - | EPS next Q | -0.83 | Inst Own | 81.49% | Short Float | 14.5% | Perf Quarter | -17.18% |
| Income | -0.10B | P/S | - | EPS this Y | -29.03% | Inst Trans | 2.43% | Short Ratio | 8.53 | Perf Half Y | 82.4% |
| Sales | 0.00B | P/B | 6.2 | EPS next 5Y | -22.84% | ROA | -31.25% | Short Interest | 4.42M | Perf YTD | 67.95% |
| Book/sh | 8.54 | P/C | 6.09 | EPS past 3/5Y | -44.91% - | ROE | -33.17% | 52W High | -27.08% ($72.64) | Perf Year | 203.73% |
| Cash/sh | 8.69 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.3% | 52W Low | 213.25% ($16.91) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -4.4% | Gross Margin | - | Volatility(W/M) | 6.79% 6.32% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.08 | EPS Q/Q | -33.99% | Profit Margin | - | RSI (14) | 47.28 | Recom | 1.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.08 | Sales Q/Q | - | SMA20 | -0.29% ($53.12) | Beta | 0.16 | Target Price | $95.7 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -9.54% ($58.56) | Rel Volume | 0.95 | Prev Close | $50.29 |
| Employees | 63 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -23.32% - | SMA200 | 16.84% ($45.34) | Avg Volume(3M) | 0.52M | Price | $52.97 |
| IPO | 2024/9/13 | Option/Short | Yes/Yes | Trades | 6015 | Volume | 492,920 | Change | 5.33% |
💊 MBX Biosciences is a U.S. clinical-stage biotech company targeting endocrine and metabolic diseases. Its lead candidate is canvuparatide for chronic hypoparathyroidism, along with an obesity treatment and imapextide for postprandial hypoglycemia. The company focuses on a pipeline of candidates with validated targets and clear regulatory approval pathways.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
MBX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -29.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 81.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #79 of 594 in the industry
Based on market cap of $3B.
FAQ
What kind of company is MBX?
MBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MBX?
The market cap of MBX is approximately $2.6B, ranking 1,872 within its sector.
What is the 52-week high and low for MBX?
MBX has recorded a 52-week high of $72.64 and a low of $16.91.
